Zacks Investment Research upgraded shares of Teladoc Health (NYSE:TDOC) from a sell rating to a hold rating in a research report released on Monday.

According to Zacks, “Teladoc’s shares have outperformed industry in a year. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. It is witnessing growth in its client roster due to the addition of new clients across multiple market segments. Teladoc is witnessing an increase in revenues driven by a rise membership and visits. Nevertheless, Teladoc has incurred significant losses and has been unable to generate cash from operations. The company’s struggle may continue in the coming quarters too. Its high debt level caused a spike in interest expenses, which weighs on operating margins.”

A number of other research analysts have also commented on the company. SunTrust Banks increased their price objective on Teladoc Health to $75.00 and gave the company a positive rating in a report on Monday, March 4th. Cantor Fitzgerald reaffirmed a hold rating and issued a $70.00 target price (down previously from $83.00) on shares of Teladoc Health in a report on Wednesday, February 27th. TheStreet raised Teladoc Health from a d+ rating to a c rating in a report on Wednesday, February 20th. Berenberg Bank began coverage on Teladoc Health in a report on Thursday, January 31st. They issued a buy rating and a $80.00 target price on the stock. Finally, Robert W. Baird raised Teladoc Health from a neutral rating to an outperform rating and set a $80.00 target price on the stock in a report on Monday, January 14th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Teladoc Health has a consensus rating of Buy and a consensus price target of $81.84.

Shares of NYSE TDOC opened at $50.87 on Monday. The company has a current ratio of 8.53, a quick ratio of 8.53 and a debt-to-equity ratio of 0.41. The stock has a market cap of $3.67 billion, a PE ratio of -35.33 and a beta of 1.44. Teladoc Health has a 52 week low of $38.15 and a 52 week high of $89.05.

In other Teladoc Health news, CEO Jason N. Gorevic sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $63.16, for a total value of $1,894,800.00. Following the completion of the sale, the chief executive officer now owns 653,851 shares in the company, valued at approximately $41,297,229.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michelle Bucaria sold 1,188 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $60.00, for a total value of $71,280.00. Following the completion of the sale, the insider now owns 2,649 shares of the company’s stock, valued at approximately $158,940. The disclosure for this sale can be found here. Insiders sold a total of 125,307 shares of company stock worth $8,045,212 in the last ninety days. Insiders own 3.95% of the company’s stock.

Several hedge funds have recently made changes to their positions in the business. American Century Companies Inc. lifted its position in shares of Teladoc Health by 67.3% in the 4th quarter. American Century Companies Inc. now owns 317,951 shares of the health services provider’s stock worth $15,761,000 after acquiring an additional 127,877 shares during the period. Geode Capital Management LLC lifted its position in shares of Teladoc Health by 10.3% in the 4th quarter. Geode Capital Management LLC now owns 729,201 shares of the health services provider’s stock worth $36,146,000 after acquiring an additional 68,049 shares during the period. Norges Bank bought a new stake in shares of Teladoc Health in the 4th quarter worth approximately $32,112,000. Financial Advocates Investment Management lifted its position in shares of Teladoc Health by 56.5% in the 4th quarter. Financial Advocates Investment Management now owns 8,284 shares of the health services provider’s stock worth $411,000 after acquiring an additional 2,990 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Teladoc Health by 95.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 207,443 shares of the health services provider’s stock worth $10,282,000 after acquiring an additional 101,498 shares during the period.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Article: Cost of Capital

Get a free copy of the Zacks research report on Teladoc Health (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.